The FDA on October 21, 2022, approved IMJUDO® (Tremelimumab) in combination with IMFINZI® (Durvalumab) for adult patients with unresectable HepatoCellular Carcinoma (uHCC). IMJUDO® is a product of AstraZeneca Pharmaceuticals.
Bottom Ad
Advertisement
Subscribe
